Traumatic Brain Injury (TBI) - Drug Pipeline Landscape, 2023

Traumatic Brain Injury (TBI) - Drug Pipeline Landscape, 2023

Traumatic Brain Injury (TBI) is a disruption in the normal function of the brain that can be caused by a blow, bump or jolt to the head, the head suddenly and violently hitting an object or when an object pierces the skull and enters brain tissue. Traumatic brain injury is the leading cause of death and disability worldwide and, can be fatal especially in children and adolescents.

The most common cause of traumatic brain injury (TBI) is traffic accidents, which are mostly obstructive and are accompanied by physical or neurological disorders caused by multiple or local injuries and caused by external impact caused by coup injury that occurs on the part hitting an object and contrecoup injury that occurs on the other side due to acceleration.

Signs and symptoms of traumatic brain injury (TBI) includes loss of or decreased consciousness Loss of memory for events before or after the event (amnesia), focal neurological deficits such as muscle weakness, loss of vision, change in speech, alteration in mental state such as disorientation, slow thinking or difficulty concentrating

Doctors most often diagnose traumatic brain injury (TBI) by quick examination of the entire body is performed, followed by a complete neurological examination. The neurological examination includes an assessment utilizing the Glasgow Coma Scale (GCS), the presence of a wide or dilated pupil on only one side suggests a large mass lesion may be present. brainstem reflexes including gag and corneal (blink) may also be tested, a computed tomography scan (CT or CAT scan) is the gold standard for the radiological assessment of a TBI.

Surgery is the most common treatment for traumatic brain injury which is performed to remove a large hematoma or contusion that is significantly compressing the brain or raising the pressure within the skull.

Report Highlights

Global Insight Service’s, Traumatic Brain Injury (TBI) - Drug Pipeline Landscape, 2023 report provides an overview of the Traumatic Brain Injury (TBI) pipeline drugs. This report covers detailed insights on Traumatic Brain Injury (TBI) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Traumatic Brain Injury (TBI) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.